Resalis Therapeutics presented preclinical data on an antisense oligonucleotide (ASO) targeting miR‑22 that the company says drives durable, metabolically healthier weight loss in animal models. At TIDES Europe the team argued the ASO acts on fat production and metabolism rather than appetite suppression, positioning the approach as an alternative to GLP‑1 peptide therapies. Resalis frames the ASO as a precision metabolic therapy to preserve muscle and bone while reducing adiposity; the program is early stage and will require translational studies and clinical validation to test safety and durable efficacy in humans.